{"id":17045,"date":"2022-04-18T14:25:56","date_gmt":"2022-04-18T08:55:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17045"},"modified":"2022-07-01T10:58:35","modified_gmt":"2022-07-01T05:28:35","slug":"aacr-2022-updates-recent-disappointment-deals-and-collaboration-of-tigit-immunotherapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/aacr-2022-updates-recent-disappointment-deals-and-collaboration-of-tigit-immunotherapies","title":{"rendered":"AACR 2022 updates, recent disappointment, deals and collaboration of TIGIT immunotherapies"},"content":{"rendered":"\n

TIGIT (T cell immunoreceptor with Ig and ITIM domains) – The red hot corner of immune-oncology market drawing huge Interest<\/strong><\/p>\n\n\n\n

Interest in TIGIT has increased since last 2-3 years and several key players are now active in this field including BeiGene\u2019s Ociperlimab, <\/strong>which is in Phase III stage of development for NSCLC; early and mid-stage active players include Innovent Biologics, BMS\/Compugen, Astrazeneca, iTeos Therapeutics\/GSK<\/strong>. Recently, in AACR, iTeos Therapeutics <\/strong>presented the data of its Anti-TIGIT Antibody, EOS-448\/GSK4428859A, <\/strong>which is being developed in collaboration with GSK<\/strong> for the treatment of cancer. In clinical studies, the treatment with EOS-448 reduces TIGIT-positive cells in tumor biopsies, which is the first evidence of a treatment impact on the tumors of patients who have been treated with an anti-TIGIT antibody. Moreover, in preclinical studies the treatment with EOS-448 reduced suppressive <\/strong>and fatigued immune cell populations in preclinical experiments and blood samples from patients with advanced malignancies, demonstrating engagement of FcR, an important component in many immune system effector activities. iTeos Therapeutics <\/strong>is being evaluated in a Phase I\/II trial in combination with Merck\u2019s Blockbuster, Keytruda  or with Inupadenant<\/strong> in patients with lung cancer, head and neck cancer, melanoma and other Advanced solid tumors (NCT05060432). <\/strong>Additionally, the company has also registered another Phase I\/II trialof its ant-TIGIT antibody in collaboration with GSK and BMS in patients with Relapsed\/Refractory Multiple Melanoma (RRMM), which is expected to initiate patient recruitment in May 2022. (NCT05289492).<\/strong><\/p>\n\n\n\n

As per the early trial data presented for the potent anti-TIGIT antibody, EOS-448, we believe that<\/em> <\/em><\/strong>it has a higher potency in cell-based assays than other anti-TIGIT monoclonal antibodies under clinical development, which may lead to its selection as a treatment candidate. However, we cannot overlook the recent failure of Roche\u2019s anti-TIGIT drug in a Phase III trial for lung cancer, and therefore should give more time to the drug to generate data from other combination trials along with Merck and BMS in the future.<\/em><\/p>\n\n\n\n

Other pharma companies, which presented the preclinical data of their TIGIT blockers include NeoImmuneTech<\/strong> and Akeso.<\/strong><\/em><\/p>\n\n\n\n

Quick Update on other TIGIT Immunotherapies<\/a>–<\/em><\/strong><\/p>\n\n\n\n